Samsung's Life Science Fund invests in Korean biotech company

Samsung's Life Science Fund has invested in AimedBio, a Korean biotech firm specializing in antibody-drug conjugates. This is the fund's fourth investment and the first in a domestic company.

A researcher at AimedBio, a local biotech company specializing in antibody-drug conjugates technology, looks at a monitor in a lab. The Life Science Fund of Samsung C&T, Samsung Biologics and Samsung Bioepis announced Wednesday that it made an equity investment in the local company. [SAMSUNG BIOLOGICS]

Samsung’s Life Science Fund made an equity investment in AimedBio, a Korean biotech company specializing in antibody-drug conjugates (ADC), Samsung Biologics said Wednesday.

This is the fund's fourth investment, and the first in a domestic company. The financial details of the investment were not disclosed.

The ADC technology enables improved anti-cancer therapeutic effects with minimum damage to non-tumor cells.

The Life Science Fund was created in 2021, with Samsung C&T investing 99 billion won ($74.4 million) and Samsung Biologics investing 49.5 billion won. Samsung Bioepis joined in with an additional 20-billion-won investment in January, bringing the total value of the fund to 170 billion won.

The fund has previously invested in Jaguar Gene Therapy and Senda Biosciences from the United States and Araris Biotech in Switzerland.

BY SHIN HA-NEE [shin.hanee@joongang.co.kr]